Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SHANGHAI, China, April 24, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, May 2nd, 2018 at 8:30am ET to discuss financial results for the full year ended December 31, 2017. On the call, Zai Lab’s senior management team will also provide the latest status update on the Company’s various development programs.
Investor Conference Call Details
Date: Wednesday, May 2nd, 2018
Time: 8:30am ET
Dial-In Details: 1-866-394-4355 (US); 1-314-888-4344 (International); 4006828609 (China)
Conference ID: 5836799
A live webcast and replay will be available on the Zai Lab investor website: http://ir.zailaboratory.com. Please note, on Monday, April 30th, 2018 Zai Lab intends to file its Form 20-F for the Year Ended December 31, 2017.
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.
Contact:
Zai Lab
Billy Cho
+86 137 6151 2501
[email protected]
Solebury Trout
John Graziano
+1 646 378 2942
[email protected]
